Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 6/20 | 0.66 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.63 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.63 |
| ▸ | GHSR | Q92847 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11517320 | 0.89 | GPBAR1 (0.66) | GPBAR1PTGS1PTGS2GHSRTDP1 | |
| SCHEMBL4333884 | 0.85 | GPBAR1 (0.60) | GPBAR1TDP1KMT2AGAAMEN1 | |
| SCHEMBL316093 | 0.83 | KMT2A (0.76) | GPBAR1PTGS1PTGS2KMT2AGAA | |
| SCHEMBL4594713 | 0.83 | GPBAR1 (0.62) | GPBAR1KMT2AGAAMEN1TSHR | |
| SCHEMBL2779302 | 0.83 | TDP1 (0.66) | GPBAR1PTGS1PTGS2GHSRTDP1 | |
| SCHEMBL3978326 | 0.82 | HTT (0.54) | GPBAR1PTGS1PTGS2GHSRTDP1 | |
| SCHEMBL3548012 | 0.82 | GPBAR1 (0.66) | GPBAR1GHSRKMT2AGAAMEN1 | |
| Hydrochloric Acid SCHEMBL4846563 | 0.82 | KMT2A (0.73) | GPBAR1PTGS1PTGS2KMT2AGAA | |
| SCHEMBL29058659 | 0.81 | KMO (0.51) | GPBAR1PTGS2KMT2AGAAMEN1 | |
| SCHEMBL30395461 | 0.81 | KMO (0.51) | GPBAR1PTGS2KMT2AGAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2768827-B1 | PROCESS FOR THE PREPARATION OF ISOXAZOLYL-METHOXY-NICOTINIC ACIDS | HOFFMANN LA ROCHE (CH) | 2016-11-23 | — | — | EP | disclosed |
| EP-2767536-B1 | Isoxazolo-pyridine derivatives | HOFFMANN LA ROCHE (CH) | 2015-09-02 | — | — | EP | disclosed |
| US-9073908-B2 | Isoxazolo-pyridine derivatives | ROCHE PALO ALTO LLC (US) | 2015-07-07 | — | — | US | disclosed |
| EP-2227467-B1 | ISOXAZOLO-PYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-12-31 | — | — | EP | disclosed |
| US-8877782-B2 | Isoxazolo-pyridine derivatives | ROCHE PALO ALTO LLC (US) | 2014-11-04 | — | — | US | disclosed |
| US-8877783-B2 | Isoxazolo-pyridine derivatives | ROCHE PALO ALTO LLC (US) | 2014-11-04 | — | — | US | disclosed |
| US-8846719-B2 | Isoxazolo-pyridine derivatives | ROCHE PALO ALTO LLC (US) | 2014-09-30 | — | — | US | disclosed |
| EP-2768827-A1 | PROCESS FOR THE PREPARATION OF ISOXAZOLYL-METHOXY-NICOTINIC ACIDS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-08-27 | — | — | EP | disclosed |
| EP-2767536-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2014-08-20 | — | — | EP | disclosed |
| US-8604062-B2 | Process for the preparation of isoxazolyl-methoxy nicotinic acids | HOFFMAN-LA ROCHE INC. (US) | 2013-12-10 | — | — | US | disclosed |
| US-7273882-B2 | Aminoacetamide acyl guanidines as β-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-09-25 | — | — | US | disclosed |
| US-20070161686-A1 | Aryl-isoxazolo-4-yl-oxadiazole derivatives | HOFFMANN-LA ROCHE INC. | 2007-07-12 | — | — | US | disclosed |
| WO-2007071598-A1 | ARYL-ISOXAZOLO-4-YL-OXADIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-28 | — | — | WO | disclosed |
| US-20070015754-A1 | Acyl guanidines as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-18 | — | — | US | disclosed |
| US-20070015754-A1 | Acyl guanidines as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-18 | — | — | US | disclosed |
| US-20070015754-A1 | Acyl guanidines as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-18 | — | — | US | disclosed |
| WO-2007002214-A2 | ACYL GUANIDINES AS BETA-SECRETASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002220-A2 | AMINOACETAMIDE ACYL GUANIDINES AS BETA-SECRETASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002220-A2 | AMINOACETAMIDE ACYL GUANIDINES AS BETA-SECRETASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060287287-A1 | Aminoacetamide acyl guanidines as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161686-A1 | Aryl-isoxazolo-4-yl-oxadiazole derivatives | GABRA5, GABRA4, GABRA3 | GPBAR1 195/4885PTGS1 3103/4885PTGS2 3664/4885 |
| US-20060287287-A1 | Aminoacetamide acyl guanidines as beta-secretase inhibitors | APP, BACE1, BACE2 | GPBAR1 828/4885PTGS1 752/4885PTGS2 612/4885 |
| US-20070015754-A1 | Acyl guanidines as beta-secretase inhibitors | BACE1, APP, BACE2 | GPBAR1 500/4885PTGS1 782/4885PTGS2 1447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.